March 17, 2016: Here are four stocks trading with heavy volume among 60 equities making new 52-week lows in Thursday’s session. Valeant Pharmaceuticals International Inc. (NYSE: VRX) dropped another 11.4% on Thursday…
One analyst firm believes the development of abuse-deterrent formulations (ADF) of opioids creates a risk that older non-ADFs may be removed from the market, creating a huge risk and opportunity in the…
The February 29 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks short interest decreased.
The February 12 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest increased.
Here are six biotech and pharma stocks that analysts are telling their firm's clients to buy now for solid upside opportunities ahead.
The January 29 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest increased.
The January 15 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest was mixed.
The short interest data have been released for the December 31 settlement date. For most of the selected pharmaceutical stocks short interest was up.
Merrill Lynch has made many updates to its various lists, and one such list is the Top US Ideas for the first quarter of 2016.
Which well-known and large cap stocks to do the major analysts on Wall Street like for 2016? Here are 10.
These specialty pharmaceutical stocks have tremendous upside potential for 2016 and could be offering investors outstanding entry points at current trading levels.
The short interest data have been released for the December 15 settlement date, and for most of the selected pharmaceutical stocks short interest was up.
The November 30 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest was up.
Teva Pharmaceutical Industries Limited (NYSE: TEVA) had a very hard time getting off the ground from 2011 through the start of 2014. This is the world’s top generic drug maker, and shares…
Jon C. Ogg Mylan announced Monday that it would be conducting a share repurchase for up to $1 billion, in a much faster timeline for repurchasing than most companies would give.
